Q-omics provides the consensus-scored KRTAP13-2 profile across patient tissues and cancer cell-line models. KRTAP13-2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KRTAP13-2 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, KRTAP13-2 RNA expression shows 6,459 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, COAD, and STAD as cancer lineages where KRTAP13-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP13-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP13-2 survival associations across molecular data types. KRTAP13-2 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP13-2 RNA expression–survival associations across cancer types. High KRTAP13-2 expression shows unfavorable associations in MESO, COAD, UVM, KIRP and SKCM, but favorable associations in PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KRTAP13-2 RNA expression.
This table summarizes KRTAP13-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP13-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP13-2 shows lower tumor expression in COAD, READ, HNSC and KIRP and higher tumor expression in KICH and PRAD. The COAD box plot shows higher KRTAP13-2 RNA expression in normal versus tumor tissue (log2 FC = −2.390, t-test p < 0.001).
This table shows molecular features associated with KRTAP13-2 in patient tissues and cancer cell lines. In patient samples, KRTAP13-2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP13-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
